Frank Mottola - 25 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Tech. Ops. Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
25 Feb 2026
Net transactions value
-$49,524
Form type
4
Filing time
26 Feb 2026, 16:19:59 UTC
Previous filing
25 Feb 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mottola Frank SVP, Chief Tech. Ops. Officer C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 26 Feb 2026 0001804567

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Award $0 +1,875 +11% $0.000000 19,083 25 Feb 2026 Direct
transaction SUPN Common Stock Tax liability $49,524 -977 -5.1% $50.69 18,106 25 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -1,875 -50% $0.000000 1,875 25 Feb 2026 Common Stock 1,875 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.